Stocks · News reference

FDA Provides Orphan Drug Designation To X4 Pharmaceuticals' Mavorixafor To Treat Congenital

Aug 26, 2026, 4:54 PMBenzinga Newsdesk

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=919722

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 10, 2026, 12:02 PMAvi Kapoor
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading include NAMI, BNED, YXT, TENX, MSC, B, VRSK, XFOR, HELP, and SLDB.
Read original at benzinga
AIRS B BNED HELP KMT
BenzingaAug 7, 2026, 4:04 PMBenzinga Newsdesk
X4 Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.
Read original at benzinga
XFOR
BenzingaAug 6, 2026, 9:22 PMBenzinga Newsdesk
X4 Pharmaceuticals Q2 EPS $(0.13) Beats $(0.18) Estimate, Sales $8.806M Beat $2.420M Estimate
X4 Pharmaceuticals (NASDAQ:XFOR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 96.25 percent increase over losses of $(3.47) per share
Read original at benzinga
XFOR